This trial is testing a new RA drug to see if it is safe and effective.
1 Primary · 6 Secondary · Reporting Duration: up to Day 35
Experimental Treatment
75 Total Participants · 3 Treatment Groups
Primary Treatment: IA-14069 · Has Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Age 18 - 70 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: